ARENSIA Spotlight Session, November 07th, Boston, MA

We are pleased to announce ARENSIA Spotlight Session "Innovative Strategies to Achieve First Efficacy Data / Proof-of-Concept in Record Time", which will take place on 24th May 2017 in San Francisco, CA.

In today's fast-changing world, to stay competitive means to be innovative and open to embrace new approaches. Industry is facing time-pressing competition when fast movement through exploratory clinical phase is posing great...

ARENSIA Opening a new Clinical Research Unit for multi-therapeutic indications Kiev, Ukraine

As consequence of the increasing demand for ARENSIA┬┤s capabilities as a specialist for early clinical trials in patients, as of August 2017, ARENSIA expands its operations with a new clinical research unit in Kiev, Ukraine.

Ukraine (45 Mio. inhabitants) with its densely populated capital Kiev (5 Mio. inhabitants) offers tremendous opportunities for efficient and high quality performance of clinical trials. The country has a centralized healthcare system with well trained medical personnel and a long tradition in clinical research.

The ARENSIA unit is dedicated to perform Phase Ib, IIa,...

ARENSIA Spotlight Session, May 24th, San Francisco, CA

We are pleased to announce ARENSIA Spotlight Session "Innovative Strategies to Achieve First Efficacy Data / Proof-of-Concept in Record Time", which will take place on 24th May 2017 in San Francisco, CA.

In today's fast-changing world, to stay competitive means to be innovative and open to embrace new approaches. Industry is facing time-pressing competition when fast movement through exploratory clinical phase is posing great challenges. Early go/no-go...

2016 In Review: Message from CEO and Co-Founder Claudia Hesselmann

At ARENSIA, we are looking back on a very good business year, in which we were able to outdo ourselves with regard to outstanding patient enrolment rates in complex Phase 1, 2a, POC studies at our Phase 1 units in Eastern Europe. Studies involved sophisticated logistics, biomarker assessments (e.g. biopsy collection and imaging), intensive PK, hospitalization, in various indications and in populations.

We continue observing high interest from Sponsors in "integrated" protocol designs: First-in-Man in healthy volunteers performed at Phase 1 CROs in Western Europe or US +...

NEW PHASE I UNIT FOR PEDIATRICS STUDIES, BUCHAREST, ROMANIA

As of August 2015, ARENSIA expands its operations with a new clinical research unit in Bucharest, Romania.

This unit is fully dedicated to exploratory clinical trials Phase 1 and 2 in PEDIATRIC patients (age 0-18) with chronic and acute conditions, such as:

-       Respiratory

-       Immunology (incl. rheumatology & allergies)

-       Eye condition (retinopathy of prematurity)

-      ...

Contact

ARENSIA Exploratory Medicine GmbH

Merowingerplatz 1
40225 Duesseldorf, Germany

Email: undefinedinfo(at)arensia-em.com

Office phone: +49 (211) 15 77 89 0
Office fax:      +49 (211) 15 77 89 10

undefinedContact form